Physician profile
Steven Conrad
NPI 1124048004
$14,528.66
in general payments reported to CMS, 2019-2025
29 companies · $842 in 2025
The $842 reported for 2025 was more than what 75% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $372 · 2021: $10K · 2022: $1,034 · 2023: $1,508 · 2024: $393 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $9,887.72 | 2021 | |
| Livanova USA, INC. | $800.00 | 2023 | Hemolung Cartridge Kit |
| Abiomed | $751.01 | 2021-2024 | Impella |
| Astrazeneca Pharmaceuticals Lp | $467.32 | 2020-2025 | Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $359.43 | 2022-2025 | Opsumit, Uptravi |
| Nxstage Medical, INC. | $325.87 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $250.00 | 2023-2025 | Nuzyra |
| Baxter Healthcare | $224.59 | 2020-2022 | |
| La Jolla Pharmaceutical Company | $171.02 | 2024-2025 | Xacduro, Giapreza, Zevtera |
| Chiesi USA, INC. | $147.42 | 2024 | Cleviprex |
| Abbvie INC. | $139.79 | 2023-2025 | Dalvance |
| Michigan Critical Care Consultants, INC. | $125.77 | 2023 | |
| Glaxosmithkline, LLC. | $125.00 | 2025 | Nucala |
| Genzyme Corporation | $125.00 | 2025 | |
| Gilead Sciences, INC. | $124.99 | 2023 | Veklury |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $109.27 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.01 | 2019-2023 | Ofev |
| Mallinckrodt Enterprises LLC | $95.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.35 | 2025 | Glassia |
| Vapotherm INC | $27.40 | 2020 | |
| Insmed, INC. | $26.35 | 2021-2022 | |
| Genentech USA, INC. | $26.22 | 2022 | |
| Resmed Corp | $20.45 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.32 | 2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $16.08 | 2024 | Terlivaz |
| Merck Sharp & Dohme LLC | $12.97 | 2023 | Dificid, Zerbaxa, Recarbrio |
| Pfizer INC. | $12.92 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.